RT Journal Article
SR Electronic
T1 Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.181072
DO 10.3899/jrheum.181072
A1 Sibel Z.  Aydin
A1 Joanna C.  Robson
A1 Antoine G.  Sreih
A1 Catherine Hill
A1 Fatma Alibaz-Oner
A1 Sarah Mackie
A1 Susan Beard
A1 Ahmet Gul
A1 Gülen Hatemi
A1 Tanaz A.  Kermani
A1 Alfred Mahr
A1 Alexa Meara
A1 Nataliya Milman
A1 Beverley Shea
A1 Gunnar Tómasson
A1 Peter Tugwell
A1 Haner Direskeneli
A1 Peter A.  Merkel
YR 2019
UL http://www.jrheum.org/content/early/2019/05/13/jrheum.181072.abstract
AB Objective The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV). Methods An international Delphi exercise conducted among investigators identified items considered important to measure active disease. In parallel, qualitative research with patients was conducted, including interviews and focus groups. Results Next steps prioritized by the group for LVV include (1) defining disease states (remission, flare, and patient-acceptable symptom state) and (2) selection of patient-reported outcome tools. Conclusion The ultimate goal is to develop an OMERACT-endorsed core set of outcome measures for use in clinical trials of LVV.